CTOs on the Move

Trevena

www.trevena.com

 
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.trevena.com
  • 955 Chesterbrook Boulevard Suite 110
    Chesterbrook, PA USA 19087
  • Phone: 610.354.8840

Executives

Name Title Contact Details

Similar Companies

Leap Biosystems

Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers.

Greater Washington Maternal-Fetal Medicine and Genetics

Greater Washington Maternal-Fetal Medicine and Genetics is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NexImmune

NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.

Creo

Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Founded in 2016 and based in California, Creo`s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet. Creo`s technology partner and major shareholder is industry-leading biotech firm Genomatica.